Expert Insights on Highlights From ASH 2020 on Lymphomas/CLL
Listen to Jeremy S. Abramson, MD, MMSc, discuss the presentations from ASH 2020 that he expects to affect practice in the management of patients with lymphomas/CLL.
Decera Clinical Education Oncology Podcast · Jeremy S. Abramson MD MMSc
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Jeremy S. Abramson, MD, MMSc, discusses highlights of the key data from ASH 2020 on the treatment of patients with lymphomas/CLL, with topics including:
- Approved and Investigational Targeted Therapeutics for CLL
- Investigational CAR T-Cell Therapy for Indolent Lymphomas, CLL, and Mantle Cell Lymphoma
- Bispecific Antibodies and Other Investigational Targeted Agents for Lymphomas
- Treatment for Older Patients With Hodgkin Lymphoma
Presenters:
Jeremy S. Abramson, MD, MMSc
Associate Professor
Department of Medicine
Harvard Medical School
Director, Center for Lymphoma
Massachusetts General Hospital
Boston, Massachusetts
Content based on an online CME program supported by educational grants from Amgen; AstraZeneca; Bristol-Myers Squibb; Epizyme, Inc.; GlaxoSmithKline; Incyte Corporation; Janssen Biotech; Karyopharm Therapeutics Inc.; Novartis; PharmaEssentia Corp.; Seattle Genetics; and Takeda Oncology.
Link to full program:
https://bit.ly/3tyQ9nG
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.